Kristi Rosa


Olaparib falls short as add-on to durvalumab in mUC, but combo may benefit HRR+ subgroup

February 19, 2022

BAYOU trial results showed no significant PFS boost in all-comer population with addition of olaparib to frontline durvalumab in metastatic urothelial carcinoma, but potential benefit for combo was observed in HRR-mutation–positive subgroup.